The company is focused on discovering and developing pharmaceuticals for the treatment of diseases such as Parkinson’s and Alzheimer’s, as well as behavioral disorders including depression, anxiety, schizophrenia, obesity, and addiction. Nura's programs are centered around G Protein-coupled receptor (GPCR) and phosphodiesterase (PDE) targets expressed in the brain, with a focus on schizophrenia, pain, and attention-deficit hyperactivity disorder.